Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Advocacy Organization to Work with Health Canada with the Goal to Gain Approval
PHILADELPHIA, Aug. 08, 2017 (GLOBE NEWSWIRE) — Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian advocates for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The meeting was lead by Millions Missing Canada and a Canadian physician representing Canadian patients with ME/CFS, in support of a collaborative effort to advance ME/CFS research and potential treatments in Canada. This joint effort, which includes Dr. Ian Hyams, a leading physician specializing in ME/CFS management is the next step to bringing Ampligen® to Canadians suffering from the disease.